The FDA approved dabrafenib plus trametinib for the anaplastic thyroid cancer (ATC) with BRAF-V600E mutation in May 2018, as well as for the adjuvant treatment of BRAF V600E/K-mutated melanoma in April 2018. Here, BRAF is linked to melanoma.